Risedronate Sodium Hydrate

利塞膦酸钠

Report date: 2023/08/16 10:52:17
NME

Base Information

Drug NameRisedronate Sodium Hydrate
Drug Alias NameSodium Risedronate利塞膦酸钠水合物利塞膦酸Optinate SeptimumActonel +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFarnesyl diphosphate synthase inhibitors
TargetsFarnesyl diphosphate synthase
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisMenopausal symptomsRenal Insufficiency, Chronic +[15] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisOsteitis DeformansOsteoporosis, Postmenopausal +[4] 
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryUnited States
Original Approved Date1998/03/27
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesProcter & Gamble Company
China Registration ClassN/A

Develop Information

Active CompaniesAjinomoto Co IncWake Forest University Health SciencesAllergan Pharmaceuticals International Ltd +[7] 
Inactive CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979University of ZurichSanofi +[9] 
Active IndicationsGlucocorticoid-induced osteoporosisOsteitis DeformansOsteoporosis, Postmenopausal +[6] 
Inactive IndicationsMenopausal symptomsRenal Insufficiency, ChronicSpinal Cord Injuries +[9] 

Other Information

ATC CodeM05BA07
Related LinksWikipediaDrugBankKEGG